Avantect Pancreatic & Ovarian Cancer Detection Blood Testing

‍

‍

For many, breast cancer risk is part of a broader genetic and clinical risk profile. Alongside established imaging, emerging blood-based testing options are now available to assist in earlier investigation of cancers historically challenging to detect early.

‍

Ovarian and pancreatic cancers remain two of the most challenging cancers to detect early. Their symptoms are often vague, subtle, and easily mistaken for everyday issues, meaning many patients are diagnosed far too late, when treatment options are limited.

‍

To complement a comprehensive risk assessment, Avantect Early Detection Testing for Pancreatic & Ovarian Cancers is now available nation-wide.

‍

This testing, an Australian first brought by BCAL Diagnostics, is designed to support clinicians in identifying potential cancer signals earlier, particularly in patients with elevated risk profiles. It may be considered as part of a broader discussion around personalised risk, alongside appropriate imaging, genetic counselling, and specialist input.

‍

Ovarian Cancer

Ovarian cancer is closely linked to hereditary breast cancer syndromes. Unlike breast cancer, ovarian cancer does not have an effective routine screening pathway, and symptoms are often subtle or mistaken for common benign conditions. As a result, approximately 70% of cases are diagnosed at an advanced stage.

Pancreatic Cancer

Known for progressing quietly, pancreatic cancer is frequently detected at late stages. Early diagnosis dramatically improves outcomes — but remains difficult with current methods.

‍

This is why early detection matters more than ever.

‍

To learn more about the test and how to access it, visit: earlydetection.com.au or email earlydetection@cancercarediagnostics.com.au.